Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Basaglar vs Lantus in Type 1 Diabetes (ELEMENT 1)
NCT01421147Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2011
- Primary completion
- Aug 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of insulin glargine in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change From Baseline in Hemoglobin A1c at 24 weeks. Started Aug 2011; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT01421147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01421147.